옵션 체인은 다양한 행사가격과 만기일에 대한 Axogen의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Axogen에 대한 시장 심리를 평가합니다..

Axogen (NASDAQ:AXGN) 주식, 옵션 체인

Axogen

AXOGEN INC

Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.

Axogen Inc

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Telix Pharmaceuticals Ltd. (TLPPF – Research Repor...

Analysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals Ltd. (OtherTLPPF), Fortrea Holdings Inc. (FTRE) and AxoGen (AXGN)

Leerink Partners analyst Mike Kratky reiterated a Buy rating on AxoGen (AXGN – Research Report) on November 7 and set a price target of $18.00. Mik...

AxoGen's Sales Surge and Strategic Leadership Inspire a Buy Rating Amidst Growth Opportunities

The medical device sector is evolving, driven by rising demand for precision technology in diagnostics. Therefore, it could be ideal to buy fundamentally solid medical device stocks Stryker Corp (SYK), Axogen (AXGN), and Zimmer Biomet Holdings (ZBH), which look poised for substantial growth. Read more… With an aging population and a rise in chronic health issues, medical technology innovations are rapidly becoming essential in healthcare, enabling quicker diagnoses and improved patient outcomes. The medical device industry is experiencing dynamic growth fueled by advancements in technology and increasing demand for innovative healthcare solutions.
Given this landscape, investors might consider investing in three fundamentally strong medical devices stocks, Stryker Corporation (<a href="https://stocknews.com/stock/SYK/">SYK</a>), Axogen, Inc. (<a href="https://stocknews.com/stock/AXGN/">AXGN</a>), and Zimmer Biomet Holdings, Inc. (<a href="https://stocknews.com/stock/ZBH/">ZBH</a>), that are well-positioned for potential growth.
Medical device companies specializing in surgical robotics, imaging, diagnostics, and portable health monitoring devices are delivering innovative products that meet the rising demand for efficient and less invasive treatments. The <a href="https://blog.bccresearch.com/the-growing-market-for-elderly-and-disabled-assistive-devices">key market driver in this sector</a> is the aging population, rising awareness and accessibility, and a surge in technological advancements.
As per the <a href="https://www.medicaldevice-network.com/sponsored/ageing-in-the-digital-era-the-surge-of-medical-device-innovation-for-older-adults/">World Health Organization (WHO), the global population aged 60</a> and above will double to 2.1 billion by 2050. This demographic shift means the role of medical devices will be more crucial than at other times in history.
Healthcare providers and patients alike are prioritizing convenience and precision, pushing for technologies that aid in real-time monitoring and minimally invasive procedures. The <a href="https://www.advamed.org/medical-device-industry-facts/">United States is the largest medical device market in the world</a>, compromising over 40% of the global MedTech market, providing physicians and other healthcare providers with the best tools to diagnose and treat patients.
According to a KPMG report, the medical device industry is poised for steady growth, with global <a href="https://kpmg.com/us/en/articles/2023/medical-devices-2030.html">annual sales forecasted to reach nearly $800 billion by 2030</a>, with a rise of over 5% a year. Companies in this space benefit from long-term demand as healthcare spending remains resilient.
Now, let's take a closer look at the fundamentals of the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> stocks mentioned above, beginning with the third choice.
Stock #3: Stryker Corporation (<a href="https://stocknews.com/stock/SYK/">SYK</a>)
Stryker Corporation operates as a medical technology company. The company operates through two segments: MedSurg and Neurotechnology, and Orthopaedics and Spine. 
On October 1, SYK announced the completion of the <a href="https://www.investopedia.com/terms/a/acquisition.asp">acquisition</a> of its Vertos Medical Inc., a leader in interventional pain management solutions for chronic lower back pain caused by lumbar spinal stenosis. This acquisition enhances non-surgical solutions with minimal invasive wild procedures for SYK.   
On September 17, SYK announced that it completed its acquisition of care.ai, a privately held company specializing in delivering AI-assisted virtual care workflows, smart room technology, and ambient intelligence solutions. This acquisition should strengthen Stryker's growing healthcare IT offering and wirelessly connected medical device portfolio.
In the fiscal third quarter that ended on September 30, 2024, SYK's net sales increased 11.9% year-over-year to $5.49 billion. The company reported an operating income of $2.43 billion, indicating a 9.2% growth from the prior-year quarter.
SYK's adjusted net earnings came in at $1.11 billion, up 17.3% year-over-year, while its adjusted earnings per share grew 16.7% from the year-ago value to $2.87.
For the full year 2024, SYK expects organic net sales to be in the range of 9.5% to 10% and adjusted net earnings diluted per share to range from $12 to $12.10.
The consensus revenue estimate of $6.36 billion for the fiscal first quarter (ending December 2024) represents a 9.4% increase year-over-year. The consensus EPS estimate of $3.87 for the same quarter indicates an 11.9% improvement year-over-year. The company has an excellent surprise history; it surpassed the consensus revenue and EPS estimates in each of the trailing four quarters.
Moreover, SYK's revenue has grown at CAGRs of 9.7% and 8.6% over the past three and five years, respectively. In addition, its EBIT increased at 8.4% CAGR over the past three years.
Over the past year, the stock has surged 33.3%, closing the last trading session at $369.02.
SYK's stance is apparent in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has a B grade for Growth, Stability, and Sentiment. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
Among the 138 stocks in the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> industry, it is ranked #46. <a href="https://stocknews.com/stock/SYK/">Click here</a> to see the additional SYK ratings (Value, Momentum, and Quality).
Stock #2: Axogen, Inc. (<a href="https://stocknews.com/stock/AXGN/">AXGN</a>)
AXGN develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company offers repair solutions for surgeons and healthcare providers. Its products include Avance nerve graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Axotouch Two-Point Discriminator, and Axoguard HA+ Nerve Protector.
On June 24, AXGN launched Avive+ Soft Tissue Matrix&#x2122;, which is used for a soft tissue barrier and is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing. This launch is a new opportunity to improve patient outcomes after acute traumatic injury.
During the third quarter that ended on September 30, 2024, AXGN's revenue increased 17.9% year-over-year to $48.64 million. The company's gross profit amounted to $36.44 million, reflecting an increase of 14.9% from the prior-year quarter.
Its adjusted EBITDA of $6.49 million, indicating a 175.6% growth from the prior-year quarter. In addition, AXGN's adjusted net income amounted to $3.15 million and $0.07 per share, reflecting considerable increases year-over-year.
Looking ahead, AXGN anticipates annual revenue for fiscal year 2024 to fall between $182 million and $186 million. The company also projects gross margin to be in the range of 74% to 76%.
Analysts expect AXGN's revenue for the fiscal year (ending December 2024) to increase 16.1% year-over-year to $184.60 million.
Over the past three and five years, AXGN's revenue income grew at CAGRs of 9.9% and 12.5%, respectively, while its total assets grew at 3.8% CAGR over the past five years.
The stock has gained 290.1% over the past year and 170.4% over the past six months to close the last trading session at $15.33.
AXGN's POWR Ratings reflect its promising outlook. The stock has an overall rating of B, which equates to Buy in our proprietary rating system.
AXGN has an A grade for Growth and B for Sentiment. It is ranked #35 in the Medical - Devices &amp; Equipment industry. <a href="https://stocknews.com/stock/AXGN/">Click here</a> to see the other ratings of AXGN for Value, Momentum, Stability, and Quality.
Stock #1: Zimmer Biomet Holdings, Inc. (<a href="https://stocknews.com/stock/ZBH/">ZBH</a>)
ZBH is a global medical technology company that designs, manufactures, and markets orthopedic reconstructive products, like knee and hip products, S.E.T. products, and craniomaxillofacial and thoracic products.
On August 7, ZBH signed an agreement to acquire OrthoGrid Systems, Inc., a privately held medical technology company focused on AI-driven surgical guidance systems for total hip replacement. This acquisition will help ZBH address the challenges of orthopedic problems with innovative technology solutions.
For the third quarter of 2024, which ended on September 30, ZBH's total revenues increased 4% year-over-year to $1.82 billion. Its operating profit rose 4.8% from the year-ago value to $279.50 million. The company's adjusted net earnings stood at $353.20 million, up marginally year-over-year, while its adjusted EPS for the quarter increased 5.5% year-over-year to $1.74.
According to the company's financial guidance for fiscal year 2024, ZBH forecasts revenue between 3.5%-4%. The company also expects adjusted diluted EPS to be between $7.95 and $8.05.
Street expects ZBH's revenue for the fiscal fourth quarter (ending December 2024) to increase 3.9% year-over-year to $2.02 billion. Its EPS for the same period is expected to register a 4.3% growth from the prior year, settling at $2.30. In addition, it surpassed the consensus revenue and EPS estimates in each of the trailing four quarters, which is excellent.
ZBH's normalized net income has grown at CAGRs of 8.7% and 3.8% over the past three and five years, respectively. Likewise, the company's levered FCF has increased at a CAGR of 2.2% over the past five years.
ZBH's stock has surged 5.2% over the past month to close the last trading session at $110.17.
ZBH's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
It also has a B grade for Growth and Value. Within the same industry, it is ranked #17 out of 328 stocks. <a href="https://stocknews.com/stock/ZBH/">Click here</a> to see ZBH's ratings for Momentum, Stability, Sentiment, and Quality.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
SYK shares were trading at $369.10 per share on Thursday afternoon, up $0.08 (+0.02%). Year-to-date, SYK has gained 24.10%, versus a 26.40% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: ShreyaRathi</h2> <img src='https:/wp-content/uploads/2024/10/0.jpeg' style="float:left; padding:5px;width:125px;"><a href="https://stocknews.com/authors/?author=shreya-rathi">More...</a>The post <a href=https://stocknews.com/news/syk-zbh-axgn-3-medical-devices-stocks-poised-for-solid-growth/>3 Medical Devices Stocks Poised for Solid Growth</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Medical Devices Stocks Poised for Solid Growth

Top 10 most expensive stocks (only 1 gets a Quant Sell)

Leerink Partners analyst Mike Kratky maintained a Buy rating on AxoGen (AXGN – Research Report) on November 25 and set a price target of $0.00. The...

Leerink Partners Reaffirms Their Buy Rating on AxoGen (AXGN)

Axogen: Well Placed To Capitalize Growth At Higher Multiples

Axogen sees Q4 revenue to be $49.4M

The company said, "Full-year 2024 revenue is expected to be approximately $187.3 million, which represents a 17.8% increase over the full-year of 2...

AxoGen sees Q4 revenue $49.4M, consensus $47.44M

The latest announcement is out from AxoGen ( ($AXGN) ). Axogen, Inc. announced its preliminary unaudited financial results for the fourth quarter a...

Axogen Reports Strong Revenue Growth and Market Expansion

Top SA Quant-rated medical devices stocks as technicals look strong

AXGN

BFLY

CERS

CFLT

CLPT

CNMD

DCTH

ECOR

EMBC

ENOV

FNKO

FTRE

GKOS

GTLB

INGN

INSG

KRMD

LNSR

MSGS

NPCE

PRCT

RMTI

SIBN

SMTI

TLPPF

ULCC

VRTX

News

Press Releases

Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

Earnings

Axogen, Inc. Reports Second Quarter 2024 Financial Results

Management

Axogen, Inc. Announces New Leadership Appointments

Health Care

CytoSorbents Appoints Peter J. Mariani Chief Financial Officer

Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4)

Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®

Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024

Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update

Economics

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024

Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Comments

Axogen

Axogen (AXGN) 옵션

Axogen (NASDAQ:AXGN) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌